This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second Look: Re-examining the safety of JAK inhibitors such as Xeljanz (tofacitinib) by Pfizer for the treatment of chronic inflammatory disorders.
Ticker(s): PFEWho's the expert?
- Rheumatologist that oversees 1500 patients
- Very familiar with the new safety data on Xeljanz
Interview GoalExamining the recent data released from the A3921133 trial of Xeljanz showing higher risk of cardiovascular problems to discern its impact on the potential use of JAK inhibitors in the future.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
